anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A wearable monitoring device system includes a wearable monitoring device (WMD), including a support structure and a plurality of electrodes. A WMD data store includes parameter data that define settings of the WMD, interpreted code that provides access to the parameter data, a web server configured to serve the interpreted code. The WMD includes a WMD processor configured to execute the web server. The system includes a companion device communicatively coupled to the WMD, including a display, a companion communication module configured to communicatively couple the companion device and the WMD, and a companion data store. The companion data store includes a browser configured to render the interpreted code. A companion processor is included, configured to execute the browser.
Patients receive RNR inhibitor COH29 PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The invention concerns a human cannabis alcohol receptor protein 11 and polynucleotide encoding it. The invention also concerns the process of producing the polypeptide by recombniant DNA technique. The methods for treating many diseases e.g. neuralgia mood disorders, a variety of tumour, immunological diseases, inflammation, development disorders, infection of HIV etc. utilizing the polypeptide are disclosed. The invention discloses the antagonist against the polypeptide and therapeutics thereof. The invention also discloses the uses of the polynucleotide, which encodes a humancannabis alcohol receptor protein 11.
BACKGROUND: Hypoxic-Ischemic Encephalopathy (HIE) is a leading cause of mortality and morbidity in newborns. Recent research has shown promise in using intranasal mesenchymal stem cell (MSC) therapy if administered within 10 days after Hypoxia-Ischemia (HI) in neonatal mice. MSCs migrate from the nasal cavity to the cerebral lesion in response to chemotactic cues. Which exact chemokines are crucial for MSC guidance to the HI lesion is currently not fully understood. This study investigates the role of CXCL10 in MSC migration towards the HI-injured brain.
METHODS: HI was induced in male and female 9-day-old C57BL/6 mice followed by intranasal MSC treatment at day 10 or 17 post-HI. CXCL10 protein levels, PKH26-labeled MSCs and lesion size were assessed by ELISA, immunofluorescent imaging and MAP2 staining respectively. At day 17 post-HI, when CXCL10 levels were reduced, intracranial CXCL10 injection and intranasal PKH26-labeled MSC administration were combined to assess CXCL10-guided MSC migration. MSC treatment efficacy was evaluated after 18 days, measuring lesion size, motor outcome (cylinder rearing task), glial scarring (GFAP staining) and neuronal density (NeuN staining) around the lesion. Expression of the receptor for CXCL10, i.e. CXCR3, on MSCs was confirmed by qPCR and Western Blot. Moreover, CXCL10-guided MSC migration was assessed through an in vitro transwell migration assay.
RESULTS: Intranasal MSC treatment at day 17 post-HI did not reduce lesion size in contrast to earlier treatment timepoints. Cerebral CXCL10 levels were significantly decreased at 17 days versus 10 days post-HI and correlated with reduced MSC migration towards the brain. In vitro experiments demonstrated that CXCR3 receptor inhibition prevented CXCL10-guided migration of MSCs. Intracranial CXCL10 injection at day 17 post-HI significantly increased the number of MSCs reaching the lesion which was accompanied by repair of the HI lesion as measured by reduced lesion size and glial scarring, and an increased number of neurons around the lesion.
CONCLUSIONS: This study underscores the crucial role of the chemoattractant CXCL10 in guiding MSCs to the HI lesion after intranasal administration. Strategies to enhance CXCR3-mediated migration of MSCs may improve the efficacy of MSC therapy or extend its regenerative therapeutic window.
Meals in this condition will be delayed by 4 hours relative to the circadian alignment condition. Food intake during this period will be from 1 PM to 11 PM.
A printer blank for a computer system printer is disclosed. The blank has a contiguous pressure adhesive backed label section and may also have a larger plain paper section separated from the label section by a perforation line. The label section is comprised of a plurality of adhesive backed labels and a backing sheet, including a main label portion and at least one smaller auxiliary label. A preferred blank comprises a plurality of auxiliary labels. In use, at least one, but preferably not all, of the auxiliary labels on such a preferred blank are simultaneously removed from the backing sheet with the main label portion. Any auxiliary label(s) simultaneously removed with the main label but not printed upon are readily separated from the main label.
OBJECTIVE: Orthopaedic surgery is an effective intervention for treating the symptoms of degenerative joint disease or osteoarthritis (OA). Frequent wound dressing changes, unless clinically indicated, can disrupt the healing process and increase the occurrence of incision site contamination. Protection from contamination is critical for surgical incisions and, therefore, undisturbed wound healing (UWH) in surgical wound management is vital. This article describes a retrospective study reporting the clinical performance of a self-adherent, absorbent postoperative dressing, with a focus on dressing wear time.
METHOD: A single-centre, retrospective electronic medical record review of a convenience sample of adult patients treated with a dressing (Mepilex Border Post Op; Mölnlycke, Sweden) following elective hip or knee replacement was undertaken. Data relating to dressing wear time, rationale for dressing changes and patient-reported outcomes were extracted from a mobile health application moveUP Therapy (moveUP NV, Belgium). Health-related quality of life assessment was conducted using the EQ-5D-5L questionnaire and orthopaedic-specific quality of life (QoL) indicator tools.
RESULTS: Of the 558 records reviewed, 151 respondents (27.1%) reported outcomes relating to dressing wear time and frequency of dressing change. The average wear time of the first dressing was 13.6 days (second dressing: 5.3 days). The proportion of patients who wore the first dressing for 1-7 days, 8-13 days and for ≥14 days was 17.2%, 13.2% and 69.5%, respectively. Data from the completed questionnaires revealed improvement in QoL over time.
CONCLUSION: The results of this study are a good indicator of the suitability of the postoperative dressing for a 14-day wear time, in line with the principles of UWH.
PURPOSE: A skin external composition containing alum and sulfur is provided to quickly relieve side effects and cytotoxicity and smooth wrinkle. CONSTITUTION: A skin external composition contains 0.5-8.0 weight parts of alum, 0.001-5 weight parts o f sulfur, and pharmaceutically or cosmetically acceptable carrier. The composition additionally contains 0.5-5.0 weight parts of camphor, 0.5-5.0 weight parts of pine tree resin, 0-.1-5.0 weight parts of borax, 0.001-2.0 weight parts of silver, or 0.5-10.0 weight parts of Rutaceae. The sulfur is dissolved in alkali solution. The alkali solution is plasticized powder solution or alkali metal solution. The alum is dissolved in water, sap, or deep sea water.
Diabetic kidney disease is associated with impaired podocyte autophagy and subsequent podocyte injury. In the present invention, the inventors investigated how the calcium channel TRPC6 and the cysteine protease calpains impair podocyte autophagy in diabetic kidney disease. They demonstrated that TRPC6 knockdown in podocytes increased the autophagic flux as a result of decreased calpains activity. Diabetic kidney disease was mimicked in vivo by using both the streptozotocin-induced diabetes model upon unilateral nephrectomy and the BTBRob/ob mouse model. Diabetes resulted in increased TRPC6 expression in podocytes in vivo together with a decreased podocyte autophagic flux. Transgenic overexpression of the endogenous calpain inhibitor calpastatin as well as pharmacological inhibition of calpain activity normalized podocyte autophagic flux, reduced nephrin loss and prevented the development of albuminuria in diabetic mice. In kidney biopsies from diabetic patients the inventors confirmed that TRPC6 overexpression in podocytes correlated with decreased calpastatin expression, autophagy blockade and podocyte injury. Therefore, targeting calpain might be a promising therapeutic strategy for the treatment of diabetic kidney disease by restoring podocyte autophagy.
Systems, devices and methods for triaging health-related data, such as significant health-related events associated with health-related parameters, are disclosed. One aspect is a method for use in managing a patient's health within a patient management system. In various embodiments of the method, a number of predetermined events are accessed. The events are related to the patient's health and are identified by the patient management system. Each of the predetermined events are classified according to severity using a color-code system. In various embodiments, a red event is an imminent life threatening event, a yellow event is a serious health-related condition that is not imminently life threatening, and a green event is an event that is neither an imminent life threatening event nor a serious health-related condition. Other aspects and embodiments are provided herein.
<P>PROBLEM TO BE SOLVED: To provide a dispersion which uses a new polymer and can form stable particles in a silicone medium without adding a stabilizing polymer, and to provide a composition using the dispersion.  <P>SOLUTION: The dispersion is prepared by dispersing particles comprising at least one acrylic polymer containing a skeleton insoluble in a non-aqueous silicone medium and a portion comprising a side chain covalently bound to the skeleton and soluble in the medium, in the medium. The polymer is obtained by free-radical-polymerizing a polymerizable mixture comprising the first monomer selected from 1-3C alkyl (meth)acrylates for forming the insoluble skeleton and at least one silicone macromonomer which contains terminal groups capable of reacting in the polymerization to form the side chains, has a weight-average mol. wt. of ≥200, and occupies 0.05 to 20 wt.% of the polymer, in the presence of an addition-polymerizable monomer such as acrylic acid or methacrylic acid in the solvent.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Smooth muscle cell (SMC) phenotypic modulation, primarily driven by PDGFRβ signaling, is implicated in occlusive cardiovascular diseases. However, the promotive and restrictive regulation mechanism of PDGFRβ and the role of protein tyrosine phosphatase non-receptor type 14 (PTPN14) in neointimal hyperplasia remain unclear. Our study observes a marked upregulation of PTPN14 in SMCs during neointimal hyperplasia. PTPN14 overexpression exacerbates neointimal hyperplasia in a phosphatase activity-dependent manner, while SMC-specific deficiency of PTPN14 mitigates this process in mice. RNA-seq indicates that PTPN14 deficiency inhibits PDGFRβ signaling-induced SMC phenotypic modulation. Moreover, PTPN14 interacts with intracellular region of PDGFRβ and mediates its dephosphorylation on Y692 site. Phosphorylation of PDGFRβY692 negatively regulates PDGFRβ signaling activation. The levels of both PTPN14 and phospho-PDGFRβY692 are correlated with the degree of stenosis in human coronary arteries. Our findings suggest that PTPN14 serves as a critical modulator of SMCs, promoting neointimal hyperplasia. PDGFRβY692, dephosphorylated by PTPN14, acts as a self-inhibitory site for controlling PDGFRβ activation.
Systems and methods for generating a digital health map is provided. A system can receive, for a subject, baseline data for a first time interval comprising health metrics, behavioral metrics, and physical metrics. The system can establish, via a model, a current location of the subject on a digital health map based on at least one of the health metrics, the behavioral metrics, or the physical metrics. The system can determine, based on the model and one or more prescribed actions, a predicted path extending from the current location for a second time interval after the first time interval. The system can update the digital health map with the predicted path for the one or more prescribed actions. The system can transmit, to a computing device, the digital health map to cause the computing device to render the digital health map via a display device coupled to the computing device.
Placebo (sterile saline) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
Low molecular weight, sulfated polysaccharide derivatives (A) from native marine exopolysaccharides (EPS), excreted by marine mesophilic bacteria derived from hydrothermal media, are new. Low molecular weight, sulfated polysaccharide derivatives (A) from native marine exopolysaccharides (EPS), excreted by marine mesophilic bacteria derived from hydrothermal media, are new. (A) are prepared by: (a) radical depolymerization of native EPS to derivatives (B) of molecular weight not over 0.1 MD; (b) sulfatation of (B), optionally freeze-dried, by adding enough of at least one sulfatation agent to form (A) with a degree of substitution by sulfate 10-45wt.% of the final product; and (c) optionally dialysis. ACTIVITY : Vulnerary; Antiinflammatory; Antibacterial; Cytostatic; Immunosuppressive; Dermatological. MECHANISM OF ACTION : (A) stimulate proliferation of fibroblasts, so promote reconstruction and remodeling of injured tissues; inhibit secretion of proinflammatory cytokines (especially interleukin-1Lbeta and tissue necrosis factoralpha ) and matrix metalloproteases (especially gelatinase A and stromelysin 1) by fibroblasts; inhibit the classical complement system; promote fibroblast proliferation at the expense of myofibroblasts; and promote selective proliferation of medullar cells committed to mesenchymal differentiation at the expense of other subpopulations. A two-dimensional culture of dermal fibroblasts was incubated in nutrient medium containing 10 mu g/ml of HE 800 DRNS (produced from the exopolysaccharide of Vibrio diabolicus by depolymerization, de-N-acetylation and sulfatation). After 10 days, the number of cells was 146% of that in a control culture without HE 800 DRNS.
Chest tube management represents a major issue after lung surgery as no protocol is widely accepted and tube management is generally based on local or personal habits. Aim of this study is to evaluate the impact of a standardized protocol for chest tube management after pulmonary resections on the post-operative outcomes. We performed a single center retrospective analysis of all adult patients undergoing thoracoscopic pulmonary resection from January 2020 to December 2021. Starting from January 2021 a standardized protocol of chest tube management was applied after all procedures. Patients were divided into two groups according to the chest tube management strategy. he two groups had similar pre-operative characteristics and the extent of lung resection was comparable. Intervention group had significantly shorter time to chest tube removal (median 1 vs 3 days, p < 0.001) and post-operative length of stay (median 3 vs 4 days, p < 0.001). Despite earlier chest tube removal, there was not an increased incidence of post-removal complications. On multivariable analysis, the new chest drain management strategy was an independent predictor of earlier chest tube removal. A standardized protocol of chest tube management allows for an earlier chest tube removal and a shorter hospital stay, without an increase in post-operative complications.
The invention discloses methods for the utilization of adenosine 5′-triphosphate (ATP) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). The administration of ATP results in several therapeutic activities, which by acting in consort provide the methods for treatment of ALI and ARDS. These therapeutic activities are 1. The utility of ATP as a preferential pulmonary vasodilator, 2. The utility of the catabolic product of ATP, adenosine, as an anti-inflammatory agent, 3. The anti-thrombotic, pro-fibrinolytic activities of ATP and adenosine, and 4. The utility of ATP in improving organ and muscle function in advanced disease patients. Therapeutic compositions and procedures for treating ALI and ARDS by administration of ATP are provided.
Abnormalities in the structure and metabolic function of abdominal subcutaneous adipose tissue (aSAT) underlie many obesity-related health complications. Endurance exercise improves cardiometabolic health in adults with overweight or obesity, but the effects of endurance training on aSAT are unclear. We included male and female participants who were regular exercisers with overweight or obesity who exercised for >2 years, and cross-sectionally compared them with well-matched non-exercisers with overweight or obesity. Here we show aSAT from exercisers has a higher capillary density, lower Col6a abundance and fewer macrophages compared with non-exercisers. This is accompanied by a greater abundance of angiogenic, ribosomal, mitochondrial and lipogenic proteins. The abundance of phosphoproteins involved in protein translation, lipogenesis and direct regulation of transcripts is also greater in aSAT collected from exercisers. Exploratory ex vivo experiments demonstrate greater angiogenic capacity and higher lipid-storage capacity in samples cultured from aSAT collected from exercisers versus non-exercisers. Regular exercise may play a role in remodelling aSAT structure and proteomic profile in ways that may contribute to preserved cardiometabolic health.
Participants listened to a pregnancy-specific guided imagery recording on four separate occasions during their pregnancies. Perceived stress was measured immediately pre and post each listening session using the Perceived Stress Measure-9 (PSM-9).
OBJECTIVES: The Mitrofanoff principle has been extensively evaluated in terms of associated morbidity and mortality. However, there is limited literature specifically addressing quality of life (QoL), particularly concerning the laparoscopic procedure. The aim of this study was to assess the impact of laparoscopic appendicovesicostomy (LA) on QoL by using a specific questionnaire targeted at patients and their families.
MATERIALS AND METHODS: This observational and descriptive study involved patients who underwent LA between May 2018 and December 2023. A survey consisting of 29 questions, organized into three sections was used: satisfaction with the surgery, outcomes, and current continence status. Responses were graded according to the Likert scale (1-5) (1 = strongly disagree, 5 = strongly agree).
RESULTS: Of the 29 contacted families, 24 (82.8%) responded. The average age was 12.3 years (SD 4.4), with 75.9% being male. The primary indication for surgery was pain during urethral catheterization (69%). Mean postoperative follow-up was 36.5 months. Regarding satisfaction with surgery: overall satisfaction,hospitalization duration and pain control was rated with a score of 5 by 66.7%, 58.3% and 58.3%, respectively. In terms of outcomes: 54.2% rated aesthetic results with a score of 5, and 83.3% rated improvement in QoL with a score of 4 or 5. Concerning current continence status, 66.6% were very satisfied with the results and reported total absence of leakages or on a very specific occasion (score of 4 or 5).
CONCLUSIONS: This study supports the improvement in perceived QoL among patients requiring an LA. Overall satisfaction with the procedure and outcomes related to continence were perceived as very good by both patients and their families.
Patients will be treated by 1,25(OH)2 Vitamin D3. Oral 1,25(OH)2 Vitamin D3(Rocaltrol) by 0.25 microgram once daily at start and regulate the dose according to the changes of blood levels of 25(OH)Vit D, calcium, phosphorus, and intact parathyroid hormone.
CYP2C19 genotyping will be carried out at the end of the study period. Clopidogrel will be used for treatment for one year according to local protocol. Patients will receive clopidogrel 75 mg per day.
PURPOSE:To provide a purified immunoglobulin having low anticomplementary activity and administrable by intravenous injection, by removing coagulum from crude immunoglobulin with PEG4000 in the presence of a specific amount of aminoacetic acid, and if necessary carrying out the adsorption treatment with an anion exchange material. CONSTITUTION:Crude immunoglobulin is dissolved in the presence of 0.5-2.0% (W/V) aminoacetic acid to attain a pH of 6.0-7.0 and a protein concentration of 3.0-5.0%, and polyethylene glycol (PEG) 4000 is added to the solution in an amount of 6.0-7.0%. The produced precipitate is removed, and the obtained supernatant liquid is adjusted to 7.0-8.0pH and added with 10.0-10.5% PEG 4000. The produced precipitate is collected to obtain high-purity immunoglobulin. The anticomplementary activity of the immunoglobulin can be further decreased by dissolving the immunoglobulin and passing through an anion exchange column. The admixed PEG can be removed from the immunoglobulin by dissolving the immunoglobulin and precipitating with cold ethanol, or adsorbing the immunoglobulin to a cation exchange material, washing, and eluting with an eluent having increased salt concentration.
This is a multicenter, randomized, open-label, active comparator-controlled phase Ⅲ trial using non-inferior design. A total of 290 patients with prostate cancer who were suitable for endocrine therapy were enrolled into the screening period from D-21 to D-10 before administration. Eligible subjects were treated with bicalutamide tablets (Casodex®, 50 mg/day) from D-10 (± 3d) before administration and randomized in a 1:1 ratio to receive LY01005 3.6 mg or ZOLADEX® 3.6 mg after completion of pretreatment. All subjects were administered once every 28 days for three doses until intolerable toxicity, disease progression requiring other anti-tumor treatments, withdrawal of consent, loss to follow-up, death or the end of the whole study. Blood samples were collected at the specified time points of the screening period, before/behind each dose to detect serum testosterone, LH, FSH and PSA. Safety evaluation (including vital signs, physical examination, laboratory tests, 12 ECG, adverse events, etc.) was conducted as required in the protocol.